PRELUDE THERAPEUTICS INC's ticker is PRLD and the CUSIP is 74065P101. A total of 70 filers reported holding PRELUDE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $356,951 | -2.8% | 115,518 | +41.6% | 0.00% | – |
| Q2 2023 | $367,178 | +204.3% | 81,595 | +285.5% | 0.00% | – |
| Q1 2023 | $120,652 | -5.6% | 21,167 | 0.0% | 0.00% | – |
| Q4 2022 | $127,849 | -8.7% | 21,167 | 0.0% | 0.00% | – |
| Q3 2022 | $140,000 | +27.3% | 21,167 | 0.0% | 0.00% | – |
| Q2 2022 | $110,000 | -84.4% | 21,167 | -79.2% | 0.00% | – |
| Q1 2022 | $703,000 | -47.3% | 101,906 | -4.9% | 0.00% | – |
| Q4 2021 | $1,335,000 | -59.9% | 107,184 | +0.7% | 0.00% | -100.0% |
| Q3 2021 | $3,326,000 | -2.1% | 106,425 | -10.3% | 0.00% | 0.0% |
| Q2 2021 | $3,398,000 | -32.1% | 118,677 | +2.8% | 0.00% | 0.0% |
| Q1 2021 | $5,005,000 | -39.2% | 115,499 | +0.4% | 0.00% | -50.0% |
| Q4 2020 | $8,229,000 | – | 115,023 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Orbimed Advisors | 10,039,691 | $66,362,000 | 1.23% |
| Baker Brothers Advisors | 10,123,824 | $66,918,000 | 0.44% |
| HHLR ADVISORS, LTD. | 583,333 | $3,856,000 | 0.10% |
| CAXTON ASSOCIATES LP | 85,992 | $568,000 | 0.08% |
| Virtus ETF Advisers LLC | 24,180 | $160,000 | 0.06% |
| GSA CAPITAL PARTNERS LLP | 54,173 | $358,000 | 0.05% |
| DENALI ADVISORS LLC | 8,200 | $54,000 | 0.03% |
| PDT Partners, LLC | 12,641 | $84,000 | 0.01% |
| UBS ASSET MANAGEMENT AMERICAS LLC | 2,402,595 | $15,881,153,000 | 0.01% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 36,949 | $244,000 | 0.01% |